Mitomycin Facts Sheet

 Mitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an active medicine against many cancers. Mitomycin is a purple color powder, or liquid, and is given by intravenous route only. (

Mitomycin is chemotherapy that is given as a treatment for some types of cancer (

COMMON TRADE NAME(S): Mutamycin®  (


The Mitomycin formula


Mitomycin biosynthesis (from



  1. Haskell CM, ed. Cancer treatment, 3rd ed. Philadelphia: WB Saunders Co, 1990.       
  2. Dorr RT, Fritz WL, eds. Cancer chemotherapy handbook. New York: Elsevier Science Publishing Co Inc, 1980:548-55.       
  3. Krogh CME, ed. Compendium of pharmaceuticals and specialties, 28th ed. Ottawa: Canadian Pharmaceutical Association, 1993:761-2.       
  4. Kastrup EK, et al, eds. Facts and comparisons: Loose-leaf information service. St. Louis: JB Lippincott Co, 1993:664.       
  5. Wiebe VJ, et al. Clinical pharmacokinetics of drugs used in the treatment of breast cancer. Clin Pharmacokin 1988;15:80-93.       
  6. Torti FM, et al. The biology and treatment of superficial bladder cancer. J Clin Onc 1984;2:505-31.       
  7. McEvoy GK, ed. American hospital formulary service: Drug information 1994. Bethesda: American Society of Hospital Pharmacists, 1994:669       
  8. Bennett WM. Guide to drug dosage in renal failure. Clin Pharmacokin 1988;15:326-54.       
  9. Pinedo HM, Chabner BA, eds. Cancer chemotherapy/7: The EORTC Cancer Chemotherapy Annual. New York: Elsevier Science Publishing Co Inc, 1985:83-90.       
  10. Crooke ST, et al. Phase I study of oral Mitomycin C. Cancer Treat Rep 1976;60:1633-6.       
  11. Vermeij J, den Hartigh J, Stuurman M, et al. Relationship between clinical parameters and pharmacokinetics of mitomycin. J Cancer Res Clin Oncol 1987;113:91-4.       
  12. Knoben JE, Anderson PO, eds. Handbook of clinical drug data, 6th ed. Hamilton: Drug Intelligence Publications Inc, 1988.       
  13. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook, 2nd ed. Norwalk: Appleton & Lange, 1994:717-26.       
  14. Dorr RT. New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. Semin Oncol 1988;15(No 3 Suppl 4):32-41.       
  15. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther 1993;35:43-50.       
  16. Buzdar AU, Legha SS, Tashima CK. Adriamycin and mitomycin C: Possible synergistic cardiotoxocity. Cancer Treat Rep 1978;62:1005-6.       
  17. Riggs CE. Antitumor antibiotics and related compounds. In: Perry MC, ed. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992:337-40.       
  18. Leudke D, McLaughlin TT, Doughaday C, et al. Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer 1985;55:542-5.       
  19. Bristol Laboratories of Canada. Mutamycin package insert. Belleville, Ontario.       
  20. Trissel LA. Handbook on injectable drugs, 7th ed. Bethesda: American Society of Hospital Pharmacists, 1992.       
  21. King JC. Guide to parenteral admixtures. St. Louis: KabiVitrum Inc, 1992.       
  22. Trissel LA, Tramonte SM, Grilley BJ. Visual compatability of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991;48:988-92.       
  23. Issell BF, et al. Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer 1984;53:1025-28.       
  24. USP DI Volume I: Drug information for the health care professional, 14th ed. Rockville: United States Pharmacopeial Convention Inc, 1994:1934-7.       
  25. USP DI Volume II: Advice for the patient: Drug information in lay language, 14th ed. Rockville: United States Pharmacopeial Convention Inc, 1994:932-4.
  26. Au JL-S, Badalament RA, Wientjes MG, et al. Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial. JNCI Cancer Spectrum 2001;93(8):597-604.
Mitomycin is an Inhibitor of DNA synthesis and nuclear division. Antibacterial to gram positive, gram negative, and acid-fast bacilli.
Molecular Formula: C15H18N4O5
Molecular Weight: 334.3
CAS Number: 50-07-7
MDL Number: MFCD00078109
Quality/Application: cell culture, tested
EC Number: 2000086
Merck Index: Merck 13, 6236
Storage Temp: 2-8°C







. .



. .